怎样治疗类风湿性关节炎

如何治疗类风湿性关节炎配图，仅供参考

Different treatment modalities of rheumatoid arthritis
Because RA is an inflammatory disease,nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids have typically been used as first-line treatments. They work quickly to alleviate RA pain and joint swelling.
Methotrexate,hydroxychloroquine,sulfasalazine and,more recently,leflunomide are examples of disease-modifying antirheumatic medications (DMARDs). These slower-acting drugs,unlike NSAIDs,not only relieve symptoms but also decrease clinical and radiographic deterioration. Because their onset period spans from several weeks to months,more rapid-acting drugs,such as NSAIDs and glucocorticoids,are frequently used as ‘bridge’ treatments when starting DMARD therapy ).
[![An external file that holds a picture,illustration,etc.
Object name is IFSO_A_2341560_F0002_C.jpg](https://ncbi.nlm.nih.gov/pmc/articles/PMC11140679/bin/IFSO_A_2341560_F0002_C.jpg "An external file that holds a picture,illustration,etc.
Object name is IFSO_A_2341560_F0002_C.jpg")](https://ncbi.nlm.nih.gov/pmc/articles/PMC11140679/figure/F0002/)
[Open in a separate window](https://ncbi.nlm.nih.gov/pmc/articles/PMC11140679/figure/F0002/?report=objectonly) [Figure 2.](https://ncbi.nlm.nih.gov/pmc/articles/PMC11140679/figure/F0002/)
A diagram presenting the various treatment modalities for rheumatoid arthritis.
The therapy options for RA are classified into two categories: non-pharmacological treatment and pharmacological treatment. Physical therapy,patient counseling on lifestyle variables,and surgical procedures to remove or replace the affected joint and bone regions are examples of non-pharmacological therapies. Pharmacological therapy includes NSAIDs,which are often used solely for symptomatic therapy or until a RA diagnosis is established since these therapies relieve pain and stiffness but have little effect on disease progression.
Biological-response modifiers,the most recent class of RA medicines,have been on the market for over 10 years. Examples include infliximab,etanercept,adalimumab,anakinra,abatacept and rituximab,which have been developed to target the inflammatory mediators of tissue destruction in RA ). Many additional therapeutic compounds are in various stages of clinical development and may be available in the next few years .","department":"